Freeze drying of human serum albumin (HSA) nanoparticles with different excipients

International Journal of Pharmaceutics

Volumn 363, Issue 1-2, 2008, Pages 162-169

  Anhorn, Marion G ^a   Mahler, Hanns Christian ^a   Langer, Klaus ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Doxorubicin; Freeze drying; Human serum albumin (HSA); Lyophilisation; Nanoparticles; Poly(ethylene glycol)

Indexed keywords

CRYOPROTECTIVE AGENT; DOXORUBICIN; EXCIPIENT; HUMAN SERUM ALBUMIN; MACROGOL; MANNITOL; NANOPARTICLE; SUCROSE; TREHALOSE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; GLASS TRANSITION TEMPERATURE; LYOPHILISATE; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

CHEMISTRY, PHARMACEUTICAL; CRYOPROTECTIVE AGENTS; DOXORUBICIN; DRUG CARRIERS; DRUG STABILITY; EXCIPIENTS; FREEZE DRYING; HUMANS; MANNITOL; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; PROTEIN STABILITY; SERUM ALBUMIN; SUCROSE; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; TRANSITION TEMPERATURE; TREHALOSE;

EID: 51649118252     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.07.004     Document Type: Article

References (35)

1. Akasaka Y., Ueda H., Takayama K., Machida Y., and Nagai T. Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. Drug Des. Deliv. 3 (1988) 85-97
2. Allémann E., Gurny R., and Doelker E. Drug-loaded nanoparticles-preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39 (1993) 173-191
3. Barratt G. Colloidal drug carriers: achievements and perspectives. Cell Mol. Life Sci. 60 (2003) 21-37
4. Brannon-Peppas L., and Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56 (2004) 1649-1659
5. Carpenter J.F., Pikal M.J., Chang B.S., and Randolph T.W. Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 14 (1997) 969-975
6. Chang L.L., Shepherd D., Sun J., Ouellette D., Grant K.L., Tang X.C., and Pikal M.J. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix?. J. Pharm. Sci. 94 (2005) 1427-1444
7. Chang L.L., Shepherd D., Sun J., Tang X.C., and Pikal M.J. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: implications for the mechanism of protein stabilization in the solid state. J. Pharm. Sci. 94 (2005) 1445-1455
8. Chatterjee K., Shalaev E.Y., and Suryanarayanan R. Partially crystalline systems in lyophilization. I. Use of ternary state diagrams to determine extent of crystallization of bulking agent. J. Pharm. Sci. 94 (2005) 798-808
9. Costantino H.R. Excipients for use in lyophilized pharmaceutical peptide, protein, and other bioproducts. In: Costantino H.R., and Pikal M.J. (Eds). Lyophilization of Biopharmaceuticals vol. 2 (2004), American Association of Pharmaceutical Scientists, Arlington 139-229
10. Crowe L.M., Reid D.S., and Crowe J.H. Is trehalose special for preserving dry biomaterials?. Biophys. J. 71 (1996) 2087-2093
11. Dreis S., Rothweiler F., Michaelis M., Cinatl Jr. J., Kreuter J., and Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int. J. Pharm. 341 (2007) 207-214
12. Greenwald R.B. PEG drugs: an overview. J. Control. Release 74 (2001) 159-171
13. Johnson R.E., Kirchhoff C.F., and Gaud H.T. Mannitol-sucrose mixtures-versatile formulations for protein lyophilization. J. Pharm. Sci. 91 (2002) 914-922
14. Kim A.I., Akers M.J., and Nail S.L. The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute. J. Pharm. Sci. 87 (1998) 931-935
15. Konan Y.N., Gurny R., and Allémann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int. J. Pharm. 233 (2002) 239-252
16. Kreuter J. Evaluation of nanoparticles as drug-delivery systems. I. Preparation methods. Pharm. Acta Helv. 58 (1983) 196-209
17. Langer K. Peptide nanoparticles. In: Kumar C.S.S.R. (Ed). Biological and Pharmaceutical Nanomaterials vol. 6 (2006), Wiley-VCH Verlag GmbH 145-184
18. Langer K., Anhorn M.G., Steinhauser I., Dreis S., Celebi D., Schrickel N., Faust S., and Vogel V. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation. Int. J. Pharm. 347 (2008) 109-117
19. Langer K., Balthasar S., Vogel V., Dinauer N., von Briesen H., and Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 257 (2003) 169-180
20. Langer K., Coester C., Weber C., von Briesen H., and Kreuter J. Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. Eur. J. Pharm. Biopharm. 49 (2000) 303-307
21. Liu S.Q., and Leong K.W. Delivery of protein and low-molecular weight drug by coacervate human serum albumin and heparin. Proc. Int. Symp. Control. Release Bioact. Mater. (1997) 911-912
22. Liu W., Wang D.Q., and Nail S.L. Freeze-drying of proteins from a sucrose-glycine excipient system: effect of formulation composition on the initial recovery of protein activity. AAPS Pharm. Sci. Tech. 6 (2005) E150-E157
23. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
24. Moghimi S.M., Hunter A.C., and Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 19 (2005) 311-330
25. Passot S., Fonseca F., Alarcon-Lorca M., Rolland D., and Marin M. Physical characterisation of formulations for the development of two stable freeze-dried proteins during both dried and liquid storage. Eur. J. Pharm. Biopharm. 60 (2005) 335-348
26. Pyne A., Chatterjee K., and Suryanarayanan R. Solute crystallization in mannitol-glycine systems-implications on protein stabilization in freeze-dried formulations. J. Pharm. Sci. 92 (2003) 2272-2283
27. Sameti M., Bohr G., Ravi Kumar M.N., Kneuer C., Bakowsky U., Nacken M., Schmidt H., and Lehr C.M. Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery. Int. J. Pharm. 266 (2003) 51-60
28. Stebbing J., and Gaya A. Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer. Cancer Treat. Rev. 28 (2002) 121-125
29. Steinhauser I., Spänkuch B., Strebhardt K., and Langer K. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27 (2006) 4975-4983
30. Tang X., and Pikal M.J. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm. Res. 21 (2004) 191-200
31. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58 (2006) 1532-1555
32. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9 (2007) E128-E147
33. Wartlick H., Michaelis K., Balthasar S., Strebhardt K., Kreuter J., and Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J. Drug Target. 12 (2004) 461-471
34. Weber C., Coester C., Kreuter J., and Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int. J. Pharm. 194 (2000) 91-102
35. Yu L., Milton N., Groleau E.G., Mishra D.S., and Vansickle R.E. Existence of a mannitol hydrate during freeze-drying and practical implications. J. Pharm. Sci. 88 (1999) 196-198